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Introduction
Adoptive cell therapy, where patients are treated with
expanded autologous T cells derived from tumor speci-
mens, is currently one of the most effective treatments for
stage IV malignant melanoma. Clinical studies have indi-
cated a link between treatment with anti-CTLA-4 treat-
ment (e.g. Ipilimumab) prior to tumor removal, and a
favorable treatment response to subsequent adoptive cell
therapy.
Methods
In the current study we compared immunological pheno-
type and functionality of T cells, generated from mela-
noma biopsies, from Ipilimumab naïve patients with
patients that had received treatment with Ipilimumab
within six month prior to tumor removal. Tumor biopsies
were obtained prospectively from 32 consecutive patients
(16 treated with Ipilimumab within six months from
tumor removal and 16 Ipilimumab naive), and T cells
were cultured and expanded according to the rapid expan-
sion protocol. Expanded cells were stained for intra- and
extracellular markers and subjected to flow cytometric
analysis. Additionally, combinatorial coding with MHC-I
multimers and co-culture assays with autologous tumor
cells were performed in order to assess tumor-specific
responses.
Results
Preliminary results showed that prior Ipilimumab treat-
ment did not affect the duration of time to establish young
TIL cultures or expansion capacity of cultured T cells.
Analysis for several phenotypic markers did not reveal any
significant differences related to prior treatment, though a
trend towards higher frequency of CD8+CD28+ T cells
was demonstrated in patients treated with Ipilimumab.
Additionally, there was no difference in frequency of
tumor reactive T cells in expanded cultures. Combinator-
ial coding with MHC-I multimers revealed frequent
responses toward common tumor associated antigens
including MART-1, gp100, TRP-2, Tyrosinase and MAGE.
Experiments are ongoing and assessment of possible treat-
ment-related differences, in terms of antigen specificity or
tumor reactivity will be presented.
Conclusions
Despite indications of a favorable effect of Ipilimumab
treatment prior to adoptive cell therapy, our preliminary
results indicate that expanded TILs from ipilimumab trea-
ted and untreated patients possess comparable quantita-
tive, phenotypic and functional characteristics. Additional
experiments are needed to further scrutinize changes in
TILs as well as tumor and microenvironment which could
lead to increased clinical response to adoptive T cell ther-
apy in ipilimumab treated patients.
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